SCHEMBL23499113

SCHEMBL23499113

Cc1cc(NC(=O)c2c(C(C)C)cn(C)c2C)ccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ MAPT P10636 4/20 0.40
▸ ALDH1A1 P00352 3/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ POLB P06746 2/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ NPC1 O15118 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ MAOB P27338 2/20 0.37
▸ MAOA P21397 1/20 0.37
▸ LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21810315 0.87 ALDH1A1 (0.42) SMN1; SMN2KDM4EMAPTALDH1A1RAB9A
SCHEMBL23499073 0.82 SMN1; SMN2 (0.40) SMN1; SMN2KDM4EMAPTALDH1A1RAB9A
SCHEMBL23498802 0.82 MAPT (0.42) SMN1; SMN2KDM4EMAPTALDH1A1RAB9A
SCHEMBL23498937 0.80 DRD4 (0.44) SMN1; SMN2KDM4EALDH1A1RAB9APOLB
SCHEMBL21809610 0.77 ALDH1A1 (0.48) SMN1; SMN2KDM4EMAPTALDH1A1RAB9A
SCHEMBL25091647 0.76 NPC1 (0.41) SMN1; SMN2KDM4EMAPTALDH1A1RAB9A
SCHEMBL23499048 0.76 DRD4 (0.42) SMN1; SMN2KDM4EMAPTALDH1A1RAB9A
SCHEMBL23498776 0.75 POLB (0.40) SMN1; SMN2KDM4EMAPTALDH1A1RAB9A
SCHEMBL23498847 0.75 TSHR (0.38) SMN1; SMN2KDM4EMAPTALDH1A1RAB9A
SCHEMBL21810028 0.74 ALDH1A1 (0.38) SMN1; SMN2KDM4EMAPTALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230107941-A1 HEPATITIS B CAPSID ASSEMBLY MODULATORS VenatoRx Pharmaceuticals, Inc. 2023-04-06 — — US disclosed
WO-2021119081-A1 HEPATITIS B CAPSID ASSEMBLY MODULATORS VenatoRx Pharmaceuticals, Inc. (US) 2021-06-17 — — WO disclosed
WO-2021119081-A1 HEPATITIS B CAPSID ASSEMBLY MODULATORS VenatoRx Pharmaceuticals, Inc. (US) 2021-06-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230107941-A1 HEPATITIS B CAPSID ASSEMBLY MODULATORS HAVCR2, COPB1, HDLBP SMN1; SMN2 3117/4885KDM4E 3751/4885MAPT 1087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback